Stem Cell Clinic

Adult Stem Cell Therapy | Orthopedic Stem Cell Institute

By adminDecember 24, 2013Uncategorized

Our state-of- the- art Orthopedic Stem Cell Institute, at the base of the breathtaking Rocky Mountains, in Johnstown, Colorado, uses our own developing research to provide adult stem cell therapies promoting natural healing. We offer two revolutionary non-invasive treatments, Stem Cell therapy and Platelet Rich Plasma (PRP), which are transforming the lives of athletes and everyday people suffering with Spine and Orthopedic injuries caused by aging and degeneration. Dr. Kenneth Pettine, a world renowned spine surgeon and a pioneer in spinal stem cell therapy opened OSCI for patients seeking possible alternatives to surgery. Pettine and his staff treat patients from around the world, using the newest and most advanced technology to treat a number of conditions, including:knees, hips, spine, shoulders, feet and ankles, and other joints. Our adult stem cell therapyprocedureuses adult mesenchymal, multipotent stem cells taken from a patients own bone marrow and then injected back into the same patient into the injured, damaged, or painful area. For patients in Colorado or anywhere in the United States, we can help.About Adult Stem Cell Therapy

More here:
Adult Stem Cell Therapy | Orthopedic Stem Cell Institute

Terry discusses his bone marrow stem cell treatment from Dr Harry Adelson for spine pain – Video

By adminDecember 24, 2013Stem Cell Treatment

Terry discusses his bone marrow stem cell treatment from Dr Harry Adelson for spine pain
Terry discusses his bone marrow stem cell treatment from Dr Harry Adelson for spine pain. After 30 years of low back pain, one treatment from Dr Adelson with...

By: Harry Adelson

West Coast Stem Cell Clinic, TeleHealth, Now Offering PRP Therapy for Hip Arthritis Treatment

By adminDecember 24, 2013Stem Cell Treatment

Orange County, California (PRWEB) December 23, 2013

The top stem cell therapy clinic in California, TeleHealth, is now offering PRP therapy for hip arthritis. The treatments are often able to delay or avoid the need for joint replacement, and are administered by Board Certified doctors at two clinic locations. Call (888) 828-4575 for more information and scheduling.

Tens of millions of Americans suffer from hip arthritis, and hundreds of thousands of hip replacements are performed every year. Nonoperative treatments prior to joint replacement often consist of steroid injections for pain relief. While the joint replacement typically has excellent pain relief outcomes, there are risks involved and sometimes the eventual need for a revision procedure.

Therefore, a procedure that offers pain relief while offering the potential for joint repair is a welcome option in hip arthritis management. TeleHealth is now offering platelet rich plasma therapy, known as PRP therapy for short, to provide pain relief and potential joint regeneration. The procedure involves a simple blood draw at the office, with the blood then being spun down in a centrifuge to obtain a solution of concentrated platelets and growth factors.

The PRP is then injected into the symptomatic hip, providing an immense amount of regenerative medicine to the arthritic joint. The material then calls in the body's stem cells as well. Published studies on PRP for joint arthritis have so far shown excellent results for pain relief.

Often times, PRP therapy at TeleHealth is covered by insurance. Verification by the clinic is able to check prior to the procedure. Patients are seen from all over Southern California for treatment of hip, knee and shoulder arthritis along with tendonitis and ligament injury. This often includes athletes, weekend warriors, executives, senior citizens and more.

To receive further information on stem cell and PRP therapy for joint arthritis or soft tissue injury, call (888) 828-4575.

Stemcell Technologies – Official Site

By adminDecember 24, 2013Stell Cell Research

Product Type Please Select Specialized cell culture media Cell isolation products Antibodies Primary cells Mammalian cloning products Small molecules Contract Services Cytokines Other cell culture media, reagents & supplies Software Stem cell detection kits Training & education Proficiency testing T-shirts

Cell Type Please Select B cells Brain tumor stem cells Bronchial epithelial cells CHO cells Dendritic cells Embryonic stem cells & iPS cells (Human) Embryonic stem cells & iPS cells (Mouse) Granulocytes & subsets Hematopoietic stem & progenitor cells Hybridomas Lymphocytes Mammary epithelial cells Mesenchymal stem cells Monocytes Myeloid cells Neural stem & progenitor cells Neurons Natural killer (NK) cells Other cells Prostate epithelial cells Regulatory T cells T cells

Your area of interest Please Select Cancer Cell line development Chimerism analysis Cord blood banking Embryonic stem cell & induced pluripotent stem cell research Endothelial & angiogenic cell research Hematologic malignancies Hematopoietic stem cell research HIV HLA Hybridoma generation Immunology Immunology (Mouse) Mammary cell research Mesenchymal stem cell research Neuroscience Pharmacology, toxicology & drug discovery Prostate cell research Respiratory research Semi-solid cloning Stem cell biology Transplantation

Popular product lines Please Select AggreWell ALDECOUNT ALDEFLUOR CFU-Hill Medium ClonaCell CollagenCult EasySep EpiCult EPO-ELISA ES-Cult MammoCult MegaCult MesenCult MethoCult mFreSR mTeSR1 & TeSR2 MyeloCult NeuroCult PneumaCult-ALI Primary cells ProstaCult RoboSep RosetteSep SepMate StemAdhere STEMdiff StemSep StemSpan STEMvision TeSR-E8

The rest is here:
Stemcell Technologies - Official Site

Information on Stem Cell Research: National Institute of …

By adminDecember 24, 2013Stell Cell Research

Introduction Stem Cells are unique in that they have the potential to develop into many different cell types in the body, including brain cells, but they also retain the ability to produce more stem cells, a process termed self renewal. There are multiple types of stem cell, such as embryonic stem (ES) cells, induced pluripotent stem (iPS) cells, and adult or somatic stem cells. While various stem cells can share similar properties there are differences as well. For example, ES cells are able to differentiate into any type of cell, whereas adult stem cells are more restricted in their potential. The promise of all stem cells for use in future therapies is exciting, but significant technical hurdles remain that will only be overcome through years of intensive research.

The NINDS supports a diverse array of research on almost all stem cells, from studies of the basic biology of stem cells in the developing and adult mammalian brain to studies focusing on nervous system disorders such as ALS or spinal cord injury. For example, investigators are looking at how ES cells can be used to derive dopamine-producing neurons that might alleviate symptoms in patients with Parkinsons disease or how somatic stem cells can generate myelin producing oligodendrocytes for remyelination following acute and chronic brain injury. Although there is much promise for using stem cells to treat neurological diseases in humans, there is much work to be done before stem cell-based therapies are ready for the clinic.

The NIH Stem Cell Information Web page provides additional information about stem cell research at NIH. Also, see MedlinePlus for more health information regarding stem cells.

To learn more about investigational therapies, including stem cells, one can search the National Institutes of Health (NIH) online clinical trials database, which has information about federally and privately funded clinical research studies on a wide range of diseases and conditions. You can access this database at ClinicalTrials.gov to learn about the location of research studies in need of participants, as well as their purpose and criteria for patient participation. The NIH also maintains a clinical research website that has additional information and can be found here: NIH Clinical Research Trials and You

NINDS Repository The NINDS also supports a repository that offers human induced pluripotent stem cell (iPSC) lines for research on neurological disorders. A list of available cell lines can be found here: Human Induced Pluripotent Stem Cells

NINDS Stem Cell Research on CampusThe Intramural Research Program of NINDS is one of the largest neuroscience research centers in the world. Investigators in the NINDS intramural program conduct research in the basic, translational, and clinical neurosciences. Their specific interests cover a broad range of neuroscience research including stem cell biology. Listings of NINDS intramural researchers by laboratory affiliation and research areas are available online.

NIH Policy and ImplementationThe Director of the NINDS, Dr. Story Landis is the Chair of the NIH Stem Cell Task Force, which was created to enable and accelerate the pace of stem cell research and to seek the advice of scientific leaders in stem cell research. For comprehensive information on NIH policies related to stem cell research, visit the NIH Stem Cell Information web page.

NIH Center for Regenerative Medicine (NIH CRM)NIH CRM is a community resource that works to provide the infrastructure to support and accelerate the clinical translation of stem cell-based technologies, and to develop widely available resources to be used as standards in stem cell research. The Center provides services and information to both the intramural and extramural NIH communities that facilitate the use of stem cell technologies for therapeutic purposes and for screening efforts. Further information about NIH CRM can be found here: NIH Center for Regenerative Medicine

Funding OpportunitiesNINDS supports a wide array of stem cell research, both basic and disease-related. Funding mechanisms supported by NINDS can be found here: Funding Mechanisms

Additionally, those interested in targeted funding solicitations can search the NIH Guide for Grants and Contracts. One can do key word searches for entries such as neurological disease and stem cell or regenerative medicine. A link to the NIH Guide can be found here: NIH Guide for Grants and Contracts

See original here:
Information on Stem Cell Research: National Institute of ...

Adult stem cells suppress cancer while dormant

By adminDecember 21, 2013Uncategorized

Los Angeles, Dec 21 : Researchers at UCLA's (University of California, Los Angeles') Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have discovered a mechanism by which certain adult stem cells suppress their ability to initiate skin cancer during their dormant phase an understanding that could be exploited for better cancer-prevention strategies.

The study, which was led by UCLA postdoctoral fellow Andrew White and William Lowry, an associate professor of molecular, cell and developmental biology who holds the Maria Rowena Ross Term Chair in Cell Biology in the UCLA College of Letters and Science, was published online Dec. 15 in the journal Nature Cell Biology.

Hair follicle stem cells, the tissue-specific adult stem cells that generate the hair follicles, are also the cells of origin for cutaneous squamous cell carcinoma, a common skin cancer. These stem cells cycle between periods of activation (during which they can grow) and quiescence (when they remain dormant).

Using mouse models, White and Lowry applied known cancer-causing genes to hair follicle stem cells and found that during their dormant phase, the cells could not be made to initiate skin cancer. Once they were in their active period, however, they began growing cancer.

"We found that this tumor suppression via adult stem cell quiescence was mediated by PTEN, a gene important in regulating the cell's response to signaling pathways," White said.

"Therefore, stem cell quiescence is a novel form of tumor suppression in hair follicle stem cells, and PTEN must be present for the suppression to work."

Understanding cancer suppression through quiescence could better inform preventative strategies for certain patients, such as organ transplant recipients, who are particularly susceptible to squamous cell carcinoma, and for those taking the drug vemurafenib for melanoma, another type of skin cancer.

The study also may reveal parallels between squamous cell carcinoma and other cancers in which stem cells have a quiescent phase.

The research was supported by the California Institute of Regenerative Medicine, the University of California Cancer Research Coordinating Committee and the National Institutes of Health.

--IBNS (Posted on 21-12-2013)

"Leading Edge" Set to Produce New Content Featuring Stem Cell Therapy, with Host Jimmy Johnson

By adminDecember 21, 2013Uncategorized

(PRWEB) December 21, 2013

Stem cell therapy has a tremendous potential to cure various illnesses and injuries. Recent news items have highlighted possibilities that it could treat damaged spinal cords or revitalize hip joints. Scientists are working on stem cell remedies for dementia, heart disease and diabetes. Doctors in some countries have begun using this therapy to grow replacement body tissue and treat leukemia.

However, stem cell treatments remain controversial. Some people object to them on ethical or religious grounds. Others express concern about the safety of these newfound cures. Animal testing has revealed that minor mistakes can result in impurities that cause cells to produce tumors and other ill effects. Some patients have died after receiving experimental therapies that weren't adequately tested.

The producers of the "Leading Edge" TV series plan to release a new segment that examines this fascinating yet contentious health topic. Presenter Jimmy Johnson will offer an update on important facts and recent developments in the world of stem cell research. Viewers can benefit from the program's concise and unbiased perspective on an issue that many people have yet to learn about.

"Leading Edge" is independently distributed to local public TV broadcasters across the U.S. The national Public Broadcasting Service does not act as its distributor. To learn more about this informational series, please browse http://www.leadingedgeseries.com or send an email message to the program's producers. They can be reached at info(at)leadingedgeseries(dot)com.

Here is the original post:
"Leading Edge" Set to Produce New Content Featuring Stem Cell Therapy, with Host Jimmy Johnson

Adult Stem Cell Therapy – Regenocyte

By adminDecember 21, 2013Stem Cell Treatment

Adult stem cells circulate throughout our bodies and act as natural healers. These cells have vast potential and limitless capabilities. For more than 40 years, adult stem cells have been used to treat cancer patients. Recent advancements in stem cell therapy have been astounding. Cells from an ill patient are being used as part of the treatment. There is no possibility of the body rejecting the new tissue formed, making stem cell treatment safe and effective in achieving positive medical outcomes. It is important to note that adult stem cell therapy is not controversial because it involves the use of a patients owntissues and NOT derived from embryos. Clinical results from cardiac, pulmonary, neurological and vascular procedures have shown that the adult stem cell procedures are as safe as traditional procedures and are complimentary to current medical practice.

Adult stem cells are extracted from the patientsbone marrow and fat(adipose). At Intercellular Sciences, the naturally occurring stem cells in the blood are cultivated into millions of RegenocyteAdult Stem Cells. The Regenocyte Stem Cells areproduced inour international treatment center and are administered into the area of need for the patient. Once injected, they stimulate tissue re-growth and greater blood flow to the affected areas. The goal of the treatment is to replace damaged cells and to promote the growth of new blood vessels and tissues in order to help the target organ function at a greater capacity. There is no risk of rejection since the Adult Stem Cells received are directly from the patient.

Regenocyte Adult Stem Cell Therapy is safe, highly effective and presents minimal risk.

To find out more today, click here or call us at (866) 216-5710

Excerpt from:
Adult Stem Cell Therapy - Regenocyte

Stem Cell Research Could Lead To A Cure For Baldness, And More

By adminDecember 20, 2013Stem Cell Medicine

December 20, 2013

redOrbit Staff & Wire Reports Your Universe Online

Regenerative medicine research conducted throughout this year at the University of Southern California (USC) could lead to new ways to counter baldness and receding hairlines using stem cells.

USC Assistant Professor of Pathology Dr. Krzysztof Kobielak and his colleagues have published a trio of papers in the journals Stem Cells and the Proceedings of the National Academy of Sciences (PNAS) describing some of the biological factors responsible for when hair starts growing, when it stops, and when it falls out.

According to USC, the three studies focused on stem cells that are located in adult hair follicles. Those cells, known as hfSCs, can regenerate both hair follicles and skin, and are governed by bone morphogenetic proteins (BMPs) and the Wnt signaling pathways groups of molecules that work together in order to control the cycles of hair growth and other cellular functions.

The most recent paper, published in the journal Stem Cells in November 2013, focuses on how the gene Wnt7b activates hair growth. Without Wnt7b, hair is much shorter, the team said. Kobielaks team originally proposed Wnt7bs role in a study published this January in PNAS. That paper identified a complex network of genes, including the Wnt and BMP signaling pathways, which controls the cycles of hair growth.

Reduced BMP signaling and increased Wnt signaling activate hair growth, while increased BMP signaling and decreased Wnt signaling keeps the hfSCs in a resting state, the researchers explained. The third paper, published in Stem Cells in September, sheds new light on the BMP signaling pathway. It looked at the function of the proteins Smad1 and Smad 5, which send and receive signals that regulate hair-related stem cells during growth periods.

Collectively, these new discoveries advance basic science and, more importantly, might translate into novel therapeutics for various human diseases, Kobielak explained. Since BMP signaling has a key regulatory role in maintaining the stability of different types of adult stem cell populations, the implication for future therapies might be potentially much broader than baldness and could include skin regeneration for burn patients and skin cancer.

Other USC researchers involved in the studies include postdoctoral fellow Eve Kandyba, Yvonne Leung, Yi-Bu Chen, Randall Widelitz, Cheng-Ming Chuong, Virginia M. Hazen, Agnieszka Kobielak, and Samantha J. Butler. Funding for the research was provided by the Donald E. and Delia B. Baxter Foundation Award and National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH).

Source: redOrbit Staff & Wire Reports - Your Universe Online

Read the original:
Stem Cell Research Could Lead To A Cure For Baldness, And More

Stem cell technology

By adminDecember 20, 2013Stem Cell Medical Center

Stem cell technology is a rapidly developing field that combines the efforts of cell biologists, geneticists, and clinicians and offers hope of effective treatment for a variety of malignant and non-malignant diseases. Stem cells are defined as totipotent progenitor cells capable of self renewal and multilineage differentiation.1 Stem cells survive well and show stable division in culture, making them ideal targets for in vitro manipulation. Although early research has focused on haematopoietic stem cells, stem cells have also been recognised in other sites. Research into solid tissue stem cells has not made the same progress as that on haematopoietic stem cells. This is due to the difficulty of reproducing the necessary and precise three dimensional arrangements and tight cell-cell and cell-extracellular matrix interactions that exist in solid organs. However, the ability of tissue stem cells to integrate into the tissue cytoarchitecture under the control of the host microenvironment and developmental cues, makes them ideal for cell replacement therapy. In this overview, we briefly discuss the current research and the clinical status of treatments based on haematopoietic and tissue stem cells.

Stem cells are progenitor cells that are capable of self renewal and differentiation into many different cell lineages

Stem cells have potential for treatment of many malignant and non-malignant diseases

Peripheral blood stem cells are used routinely in autologous and allogeneic bone marrow transplantation

Gene transfer into haematopoetic stem cells may allow treatment of genetic or acquired diseases

Embryonic stem cells may eventually be grown in vitro to produce complex organs

Neuronal stem cells are being used for neurone replacement in neurovegetative disorders such as Parkinson's and Huntingdon's diseases

Haematopoietic stem cells are a somatic cell population with highly specific homing properties and are capable of self renewal and differentiation into multiple cell lineages.2 Human haematopoietic progenitor cells, like stromal cell precursors in bone marrow, express the CD34 antigen, a transmembrane cell surface glycoprotein identified by the My10 monoclonal antibody.3 However, pluripotent stem cells constitute only a small fraction of the whole CD34+ population, which is by itself rather heterogeneous regarding phenotype and function. The best way to define haematopoietic stem cells is from their functional biology. They are known to restore multilineage, long term haematopoietic cell differentiation, and maturation in lethally cytoablated hosts.4 Haematopoietic stem cells can be obtained from bone marrow, peripheral blood,5 umbilical cord blood,6 and fetal liver.7

The use of peripheral blood stem cells in both autologous and allogeneic transplantation has become routine as they can be collected on an outpatient basis and also promote a consistent acceleration in haematopoietic reconstitution after engraftment.8 Umbilical cord blood stem cells have been used progressively in paediatric patients, from both related and unrelated HLA-matched donors. In recipients with severe T cell immunodeficiency disorders, fast engraftment is required together with a low risk of graft versus host disease and a low viral transmission rate.9 Since umbilical cord blood stem cells can be expanded in vitro or frozen for storage in cell banks10 they have been used in clinical trials for both autologous and allogeneic haematopoietic stem cell transplantation.11

The bone marrow is a mesenchyme derived tissue consisting of a complex haematopoietic cellular component supported by a microenvironment composed of stromal cells embedded in a complex extracellular matrix.12 This extracellular matrix has an important role in the facilitation of cell-to-cell interaction, in addition to a more complex role in the binding and presentation of cytokines to the haematopoietic progenitor cells.13 The cytokine milieu and extracellular matrix interaction provides the road map for maturation and differentiation of stem cells,14 which should be instrumental for their in vitro manipulation before therapeutic use. For example, haematopoietic stem cells can be manipulated in vitro to generate dendritic cells, the most potent antigen presenting cells.